BRAF and melanoma: Moreover, according to one study, patients with NRAS-mutant melanomas would benefit from the administration of anti-CTLA-4 and anti-PD-1 therapies, since they demonstrated a better response to any kind of immunotherapy and an improved PFS, compared to patients with wild-type melanomas or BRAF-mutant melanomas (Johnson et al., 2015).